Table S1. Comparability of the two restricted groups across all baseline clinical parameters of
the study.
Patients that completed
Patients that did not
follow-up kidney
complete follow-up kidney
function study
function study
(n = 853)
(n = 149)
59.3 (0.3)
61.0 (0.7)
0.036
83.0
81.0
0.556
85.2 (0.5)
84.5 (1.3)
0.540
31.1 (0.2)
31.2 (0.4)
0.728
55.3
60.7
0.131
68.0
72.5
0.285
eGFR, ml/min/1.73 m2
89.5 (0.6)
87.6 (1.5)
0.190
UACR, mg/g
42.28 (4.7)
106.37 (32.3)
0.052
53.2
57.8
0.170
Fasting glucose, mg/dL
112.5 (1.3)
120.4 (4.0)
0.058
HbA1c, %
6.62 (0.04)
6.83 (0.12)
0.086
HOMA-IR
3.60 (0.30)
3.91 (0.36)
0.687
Fasting insulin, mU/L
10.9 (0.4)
11.7 (0.7)
0.441
Total cholesterol (mg/dL)
158.2 (1.1)
163.7 (2.8)
0.053
LDL-cholesterol, mg/dL
88.4 (0.9)
89.8 (2.5)
0.551
HDL-cholesterol, mg/dL
42.1 (0.3)
42.8 (0.9)
0.461
Triglycerides, mg/dL
131.9 (2.2)
136.1 (6.0)
0.470
Never smokers
27.5
20.4
0.085
Current smokers
8.9
15.6
0.012
Former smokers
63.6
63.9
0.939
Lipid-lowering drugs
86.2
82.9
0.307
Oral antidiabetic drugs
34.4
37.4
0.512
Antihypertensive drugs
89.8
91.2
0.610
Age, years
Male, %
Weight, kg
BMI, kg/m2
Obesity, %
†
Hypertension, %§
‡
Type 2 diabetes, %
p value *
Smoking habits, %
Medication use, %
Data are mean (standard error) or percentage of participants. P value for comparisons between
groups calculated with Chi-square tests for categorical variables or independent t-test test for
quantitative variables. *Low-fat diet group vs. Mediterranean diet group, p < 0.05
†
Obesity was defined as a BMI ≥30 kg/m2
§
Hypertension was defined as a systolic blood pressure ≥ 140 mm Hg, a diastolic blood pressure
≥ 90 mm Hg, or the use of antihypertensive therapy.
‡
Type 2 diabetes was defined as being diagnosed as diabetic before the start of the study (350,
34.9%) and those diagnosed by a fasting blood glucose level ≥ 126 mg/dL on two occasions, or a
2-h plasma glucose level ≥ 200 mg/dL during a 75-g oral glucose-tolerance test, during the first
procedures of the study.
CHD, coronary heart disease; BMI, body max index; eGFR, estimated glomerular filtration rate;
UACR, urine albumin-to-creatinine ratio; HbA1c, glycated hemoglobin; HOMA-IR, Homeostatic
Model Assessment for Insulin Resistance.